Two Pennsylvania announcements in early 2026 proposed more than $4.5 billion in biopharma manufacturing investment and more than 1,350 jobs over different hiring periods. These are announced commitments, not completed spending or filled positions.

Pennsylvania announced Lilly’s $3.5 billion Lehigh County project on January 30, with at least 850 jobs planned over five years. On February 18, the state announced Johnson & Johnson’s investment of more than $1 billion in Montgomery County, with more than 500 jobs planned over 12 years.

GSK also announced an Upper Merion facility in September 2025. It does not belong in the 2026 two-project total. GSK’s $1.2 billion figure covered several U.S. manufacturing and technology investments, not that one factory alone.

State officials are celebrating and the headlines write themselves.

But nobody in Harrisburg is asking the obvious question: where are the people coming from?

The Workforce Problem Nobody Wants to Talk About

I’ve spent the last decade watching pharmaceutical companies pour money into buildings and then act surprised when they can’t staff them. This is about to happen again, except this time it’s happening at a scale Pennsylvania has never seen.

Let me walk you through why.

As of late 2025, there were roughly 415,000 open manufacturing jobs across the United States. In December alone, approximately 245,000 manufacturing employees walked out the door. The Manufacturing Institute and Deloitte project that 3.8 million manufacturing workers will be needed by 2033, with up to 1.9 million of those positions potentially unfilled.

And we’re not talking about jobs where you can pull someone off a production line in Allentown and hand them a gown. Biopharmaceutical manufacturing requires people who understand biology and industrial operations under GMP simultaneously. Cell therapy manufacturing technicians need 6 to 12 months of training before they can run independently. Quality professionals need years of practical experience to be useful during an FDA inspection.

The talent pool is specialized, the regulatory environment doesn’t forgive on-the-job learning, and the pipeline to produce these workers barely exists at the volume Pennsylvania is about to need.

Here’s where it gets uncomfortable.

While Pennsylvania is attracting historic investment, the broader biopharma industry laid off 47% more workers in 2025 than in 2024. Over 180 companies let go of more than 41,000 employees through October. Bristol Myers Squibb just announced another 247 cuts at Lawrenceville, New Jersey, running through the end of 2026. Merck closed a Pennsylvania facility affecting 163 workers. Galapagos shuttered its entire cell therapy business, closing sites in both New Jersey and Pennsylvania.

So the industry is building new facilities and firing the people who know how to run them. At the same time.

It sounds contradictory, but it makes sense if you look at what’s actually happening. Companies are cutting R&D headcount, commercial roles, and corporate staff while scrambling to hire manufacturing operators, process engineers, and quality specialists. The jobs being eliminated are not the same jobs being created. A scientist who spent fifteen years in drug discovery doesn’t become a GMP manufacturing technician overnight. Different skill set. Different world.

The result is a talent bottleneck that no amount of capital investment fixes. The buildings will get built. The equipment will get qualified. But the workforce that makes a compliant cleanroom actually produce drugs? That pipeline is years behind the concrete.

The Competition Pennsylvania Isn’t Ready For … Yet

Pennsylvania isn’t competing in a vacuum, either. North Carolina has been building its biopharma manufacturing corridor for over a decade with real workforce training programs like NC State’s Biowork certification. Massachusetts has the density of talent, even after recent layoffs. New Jersey has the legacy infrastructure and proximity to corporate headquarters.

What Pennsylvania has is momentum and geography. The Lehigh Valley is within reach of major research universities. Montgomery County has deep pharma roots through existing J&J, Merck, and GSK operations. The state committed $41.5 million in incentives for the J&J facility alone.

But here’s the thing about incentives. They attract buildings. They don’t create workforces.

The states that win the next decade of biopharma manufacturing won’t be the ones that offered the biggest tax breaks. They’ll be the ones that solved the workforce problem first. The ones where a company can break ground and know, with real confidence, that the operators and quality professionals who will run the facility are already being trained somewhere nearby.

Pennsylvania doesn’t have that. Not at the scale these investments are about to demand.

Let me get specific, because this is where the conversation usually falls apart.

Lilly and J&J have announced plans for more than 1,350 jobs across the two projects. Those roles will need different combinations of manufacturing, engineering, quality, and training capabilities. Actual hiring profiles and schedules remain project-specific.

That is a substantial planned hiring need across two facilities. Building role-based training and qualification capacity alongside construction would give both employers a stronger start.

Community colleges offer some relevant coursework. University programs produce scientists, not manufacturing operators. And the existing pharma companies in the region are already fighting over the same limited talent pool, handing out signing bonuses north of $100,000 for experienced CMC leaders.

I’ve seen this movie before. Every company that announces a new facility assumes the workforce will just materialize. It almost never does on schedule. What actually shows up instead is undertrained operators running high-value batches, elevated deviation rates during the first 18 to 24 months, extended process validation timelines, and FDA scrutiny during pre-approval inspections that can push product launches back by quarters or years.

What This Means For You

If you work in quality, training, or manufacturing operations in the Mid-Atlantic region, here’s what the next three years look like for you.

If you’re a training leader, your budget conversation just changed. These projects could increase demand for a specialized workforce that turns your internal training capacity into a strategic asset, not a cost center. Document the gap. Quantify the risk. Present training infrastructure as the thing that determines whether your site hits its production timeline or misses it by a year and a half.

If you’re a QA/QC professional, your market value just went up. The demand for experienced quality professionals who can build systems from scratch at greenfield sites is about to spike across southeastern Pennsylvania. If you’ve been through a facility startup before, you’re the person these companies need.

If you’re in operations, cross-train now. The companies building these facilities want operators who can work across modalities and adapt to new SOPs without a six-month learning curve. Flexibility is going to separate the people who get hired from the people who get waitlisted.

If you’re a CDMO, Pennsylvania just became your biggest competitive threat and your biggest opportunity at the same time. If you can demonstrate workforce readiness while these facilities are still under construction, you capture the commercial manufacturing contracts that bridge the gap. If you can’t, you watch your clients move production in-house the moment those buildings come online.

More than $4.5 billion in announced projects is a meaningful investment signal. The companies and their partners still need to plan how workers will be hired, trained, and qualified for the work.

The buildings will go up. The press conferences will happen. The ribbon cuttings will make the evening news.

But the question that determines whether this becomes a real manufacturing renaissance or an expensive lesson is the simplest one nobody wants to answer: who is training the people?

Because concrete doesn’t manufacture drugs. People do.

That’s it for Issue #2. If this was useful, forward it to someone on your quality team. If you want to talk about any of this in more detail, I’m at bdrapeau@gxpframe.com.

Brian Drapeau
Founder, GxP Frame
gxpframe.com

See you next week!